Peter Hodson Luminex Corp LMNX-Q BUY Nov 07, 2008

Does pharmaceutical testing at a high throughput rate and saves pharmaceutical companies money. Just came out with great earnings. Good cost control.

Peter Hodson

Owned

Unlock Rating

$22.480

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Caller is asking about averaging down. You should never average down but you should average out with winners.

Most Recent Experts

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase Insights

5i Research

Joe Terranova

Virtus Investment Partners

Jim Lebenthal

Cerity Partners

Karen Firestone, CEO, Aureus Asset Management

Aureus Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Peter Hodson Luminex Corp LMNX-Q BUY Nov 07, 2008

You might be interested:

Luminex Corp(LMNX-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals